Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 30
    records per page




    Clinical Thrombosis MESHD Rate was not Increased in a Cohort of Cancer MESHD Patients with COVID-19

    Authors: Phaedon D Zavras; Rafi Kabarriti; Vikas Mehta; Sanjay Goel; Henny H. Billett; Johanna I. Blase; Dora Bordoni; Jeanette Franzenburg; Ulf Geisen; Jonathan Josephs-Spaulding; Philipp Koehler; Axel Kuenstner; Elisa Rosati; Anna C. Aschenbrenner; Petra Bacher; Nathan Baran; Teide Boysen; Burkhard Brandt; Niklas Bruse; Jonathan Doerr; Andreas Draeger; Gunnar Elke; David Ellinghaus; Julia Fischer; Michael Forster; Andre Franke; Soeren Franzenburg; Norbert Frey; Anette Friedrichs; Janina Fuss; Andreas Glueck; Jacob Hamm; Finn Hinrichsen; Marc P. Hoeppner; Simon Imm; Ralf Juenker; Sina Kaiser; Ying H. Kan; Rainer Knoll; Christoph Lange; Georg Laue; Clemes Lier; Matthias Lindner; Georgios Marinos; Robert Markewitz; Jacob Nattermann; Rainer Noth; Peter Pickkers; Klaus F. Rabe; Alina Renz; Christoph Roecken; Jan Rupp; Annika Schaffarzyk; Alexander Scheffold; Jonas Schulte-Schrepping; Domagoj Schunck; Dirk Skowasch; Thomas Ulas; Klaus-Peter Wandinger; Michael Wittig; Johannes Zimmermann; Hauke Busch; Bimba F. Hoyer; Christoph Kaleta; Jan Heyckendorf; Matthijs Kox; Jan Rybniker; Stefan Schreiber; Joachim Schultze; Philip Rosenstiel; - HCA Lung Biological Network; - Deutsche COVID-19 Omics Initiative (DeCOI)

    doi:10.1101/2020.09.15.20195263 Date: 2020-09-18 Source: medRxiv

    Increased rates of thromboembolic MESHD events (TE) have been reported in patients with coronavirus disease MESHD (COVID-19), even without prior predisposition to thrombosis MESHD. D-dimer levels have been shown to positively correlate with disease severity and mortality, leading to adoption of new empiric anticoagulation protocols by many centers. We aimed to assess whether COVID-19 further increased the risk of TE events in a cancer MESHD population who tested positive for COVID-19 at Montefiore Medical Center, Bronx, NY. The electronic medical records of 218 cancer MESHD patients were retrospectively reviewed up to April 10th, 2020. Work-up of thrombosis MESHD was done by the primary team upon clinical or laboratory suspicion. All imaging studies' reports, within 20 days of COVID-19 positive test, were reviewed for presence of new arterial or venous thrombosis HP venous thrombosis MESHD. Mortality was assessed up to one month since positive COVID-19 test result. Twelve patients (5.5%) were found to have new arterial (N=6, 50%) or venous (N=6, 50%) thrombosis MESHD. Five patients (41.7%) had history of prior TE events. Incidence of deep venous thrombosis HP deep venous thrombosis MESHD and pulmonary embolism HP pulmonary embolism MESHD was 1.8% and 0.5%, respectively. Arterial events occurred in the brain (66.7%), aorta (16.7%) and coronary arteries (16.7%). Median time from COVID test was 8 days (IQR, 1.5 - 11.3). Five patients (41.7%) had received either prophylactic or therapeutic anticoagulation for a median 2 days (IQR, 1 - 5). Median peak D-dimer within 36 hours of the TE event was 9.8 mcg/mL (N=4 patients, IQR, 1.7 - 18.3). Mortality did not differ significantly between the patients with new TE events vs those without; mortality 41.7% vs 37.4%, respectively, p=0.77. Empiric anticoagulation did not improve mortality. Fifty percent of all TE events were arterial. The overall TE rate of 5.5% in the cancer MESHD population was not higher than the risk of general population. Our findings support the need for larger studies in the COVID-19+ cancer MESHD population.

    Tracheal tube obstruction MESHD due to hemoptysis HP associated with pulmonary infarction MESHD in a patient with severe COVID-19 pneumonia HP pneumonia MESHD: A case report.

    Authors: Takaaki Maruhashi; Yutaro Kurihara; Tatsuhiko Wada; Mayuko Osada; Marina Oi; Tomonari Masuda; Kunihiro Yamaoka; Yasushi Asari

    doi:10.21203/rs.3.rs-75925/v1 Date: 2020-09-11 Source: ResearchSquare

    Background: The incidence of thrombotic complications MESHD is extremely high among severe coronavirus disease MESHD 2019(COVID-19) patients in the intensive care unit. Various factors such as a cytokine storm due to an excessive immune response to inflammation MESHD, hypoxemia HP hypoxemia MESHD, and disseminated intravascular coagulation HP intravascular coagulation MESHD are considered predisposing factors for thrombotic complications MESHD.Case presentation: A 55-year-old Japanese man intubated 8 days previously was referred to our hospital because of a severe COVID-19 pneumonia HP pneumonia MESHD diagnosis after his pharyngeal swab tested positive for severe acute respiratory syndrome MESHD coronavirus 2 using reverse transcription-polymerase chain reaction. The patient continued to remain hypoxic (PaO2/FiO2 ratio <100 mmHg) at the referring hospital. On admission, we initiated veno-venous extracorporeal membrane oxygenation (VV-ECMO). Unfractionated heparin and nafamostat mesylate were used as anticoagulants during VV-ECMO. Despite the adequate anticoagulant therapy, he developed pulmonary infarction MESHD due to pulmonary embolism HP pulmonary embolism MESHD followed by hemoptysis HP. On day 10 following admission, his oxygen saturation dropped from 95% to 88%, with a marked decrease in his ventilator tidal volume, accompanied by an inability to ventilate the patient. Thereafter, we increased the VV-ECMO flow and exchanged his endotracheal tube. The lumen of the removed tracheal tube was found to be occluded by a large-sized blood SERO coagulum. There was no further episode of tube occlusion MESHD. The patient was discharged in a walkable state on day 39 following admission. Conclusions: Endotracheal tube obstruction MESHD secondary to hemoptysis HP should be suggested in patients with COVID-19 requiring ventilator support, as they are not able to perform frequent endotracheal tube suctions owing to the risk of infection TRANS risk of infection TRANS infection MESHD.

    The Incidence of Pulmonary Thromboembolism in Critically MESHD Thromboembolism HP in Critically Ill Patients With COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression of Observational Studies

    Authors: Jun Jie Ng; Zhen Chang Liang; Andrew MTL Choong

    doi:10.21203/rs.3.rs-74260/v1 Date: 2020-09-08 Source: ResearchSquare

    Purpose Coronavirus disease MESHD 2019 (COVID-19) infection is known to be associated with a hypercoagulable and prothrombotic state, especially in critically ill MESHD patients. Several observational studies have reported the incidence of thromboembolic MESHD events such as pulmonary thromboembolism MESHD thromboembolism HP ( PTE MESHD). We performed a meta-analysis to estimate the weighted average incidence of PTE MESHD in critically ill COVID-19 patients who are admitted to the intensive care unit.Methods We searched MEDLINE via PubMed, Embase and Web of Science for relevant studies from 31 December 2019 till 15 Aug 2020 onwards using the search terms “coronavirus”, “COVID-19”, “SARS-CoV-2”, “2019-nCoV”, “thrombus”, “thrombo*”, “ embolus MESHD” and “emboli*”. We included prospective and retrospective observational studies that reported the incidence of PTE MESHD in critically ill COVID-19 patients who required treatment in the intensive care unit. We identified 14 studies after two phases of screening and extracted data related to study characteristics, patient demographics and the incidence of PTE MESHD. Risk of bias was assessed by using the ROBINS-I tool. Statistical analysis was performed with R 3.6.3.Results We included 14 studies with a total of 1182 patients in this study. Almost 100% of patients in this meta-analysis received at least prophylactic anticoagulation. The weighted average incidence of PTE MESHD was 11.09% (95% CI 7.72% to 15.69%, I2 = 78%, Cochran’s Q test P < 0.01). We performed univariate and multivariate meta-regression which identified the proportion of males TRANS as a significant source of heterogeneity (P = 0.03, 95% CI 0.00 to -0.09)Conclusion This is the only study that had specifically reported the weighted average incidence of PTE MESHD in critically ill COVID-19 patients using meta-analytic techniques. The weighted average incidence of PTE MESHD remains high even after prophylactic anticoagulation. This study is limited by incomplete data from included studies. More studies are needed to determine the optimal anticoagulation strategy in critically ill COVID-19 patients.

    Incidence of thromboembolism HP thromboembolism MESHD in patients with COVID-19: a systematic review and meta-analysis

    Authors: Kochawan Boonyawat; Pichika Chantrathammachart; Pawin Numthavej; Nithita Nanthatanti; Sithakom Phusanti; Angsana Phuphuakrat; Pimjai Niparuck; Pantep Angchaisuksiri

    doi:10.21203/rs.3.rs-63530/v1 Date: 2020-08-21 Source: ResearchSquare

    Background Since the beginning of the coronavirus disease MESHD 2019 (COVID-19) pandemic, the incidence of thromboembolism HP thromboembolism MESHD has been increasingly reported. The aim of this systematic review was to explore the incidence of venous and arterial thromboembolism MESHD thromboembolism HP among COVID-19 patients requiring hospitalization.Methods Medline, Embase, Scopus, and grey literature were searched until May 2020. Observational studies reported on the incidence of venous thromboembolism MESHD thromboembolism HP ( VTE MESHD), including pulmonary embolism HP pulmonary embolism MESHD ( PE MESHD) and deep vein thrombosis MESHD ( DVT MESHD) or arterial thromboembolism MESHD thromboembolism HP ( ATE MESHD) were included. The pool incidences and their 95% confidence intervals (CI) were calculated using the random-effects model.Results A total of 26 studies were included. In the intensive care unit (ICU) setting, the pooled incidence of VTE MESHD was 27% (95% CI, 20–35%). Subgroups based on compression ultrasound (CUS) screening revealed a higher incidence of DVT MESHD in the CUS screening group than in the no CUS screening group (27% [95% CI, 20–35%] vs. 3% [95% CI, 1–5%]). The pooled incidence of ATE MESHD in ICU was 3% (95% CI, 2–4%). In the non-ICU setting, the pooled incidence of VTE MESHD was 8% (95% CI, 4–12%,).Conclusions The incidence of VTE MESHD in COVID-19 patients was higher in the ICU setting than in the non-ICU setting, and also significantly higher in studies that incorporated the CUS screening protocol. The incidence of ATE MESHD in the ICU setting was low. VTE MESHD prophylactic measures should be given to all hospitalized patients diagnosed with COVID-19, especially in the ICU setting.

    Pulmonary Cavitation – An Under-recognized Late Complication of Severe COVID-19 Lung Disease MESHD

    Authors: Zaid Zoumot; Maria-Fernanda Bonilla; Ali S. Wahla; Irfan Shafiq; Mateen Uzbeck; Rania M. El-Lababidi; Fadi Hamed; Mohamed Abuzakouk; Mahmoud ElKaissi

    doi:10.21203/rs.3.rs-62904/v1 Date: 2020-08-20 Source: ResearchSquare

    Background: Pulmonary radiological findings of the novel coronavirus disease MESHD 2019 (COVID-19) have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill. However, lung cavitation has not been commonly described in these patients. The objective of this study was to assess the incidence of pulmonary cavitation MESHD in patients with COVID-19 and describe its characteristics and evolution.Methods: We conducted a retrospective review of all patients admitted to our institution with COVID-19 and reviewed electronic medical records and imaging to identify patients who developed pulmonary cavitation.Results: Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary cavitation, comprising 3.3% (n=12/359) of patients who developed COVID-19 pneumonia HP pneumonia MESHD, and 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died, two are recovering in hospital and four have been discharged home.  Conclusion: Cavitary lung disease MESHD in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.

    Pulmonary cavitation; an under-recognized late complication of severe COVID-19 lung disease MESHD

    Authors: Zaid Zoumot; Maria-Fernanda Bonilla; Ali Saeed Wahla; Irfan Shafiq; Mateen Uzbeck; Rania M El-Lababidi; Fadi Hamed; Mohamed Abuzakouk; Mahmoud El-Kaissi; Xiaoyang Ma; Tianwei Zhao; Xiaodi Guo; Zhihai Chen; Arjun Rustagi; Angela J Rogers; Nigam H Shah; Catherine A Blish; Jennifer R Cochran; Kari C Nadeau; Theodore S Jardetzky; James L Zehnder; Taia T Wang; Peter S Kim; Saurabh Gombar; Robert Tibshirani; Benjamin A Pinsky; Scott D Boyd

    doi:10.1101/2020.08.15.20175869 Date: 2020-08-17 Source: medRxiv

    Background: Radiological findings of the novel coronavirus disease MESHD 2019 (COVID-19) pulmonary disease MESHD have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, lung cavitation has not been described in these patients. Objectives: To assess the incidence of pulmonary cavitation MESHD and describe its characteristics and evolution. Methods: A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary cavitation. Results: Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary cavitation, comprising 3.3% (n=12/359) of those with COVID-19 pneumonia HP pneumonia MESHD, and 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion: Cavitary lung disease MESHD in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.

    Intracerebral hemorrhage MESHD in COVID-19 patients with pulmonary failure MESHD – a propensity score matched registry study

    Authors: Corinna N. Lang; Johanna S. Dettinger; Michael Berchtold-Herz; Stefan Utzolino; Xavier Bemtgen; Viviane Zotzmann; Bonaventura Schmid; Paul M. Biever; Christoph Bode; Katharina Müller-Peltzer; Daniel Duerschmied; Tobias Wengenmayer; Wolf-Dirk Niesen; Dawid L. Staudacher

    doi:10.21203/rs.3.rs-56258/v1 Date: 2020-08-09 Source: ResearchSquare

    Background: Hypercoagulopathy in coronavirus disease MESHD 2019 (COVID-19) causing deep vein thrombosis MESHD and pulmonary artery embolism MESHD necessitate systemic anticoagulation. Case reports of intracerebral hemorrhages MESHD in ventilated COVID-19 patients warrant precaution. It is unclear however, if COVID-19 patients with acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) with and without extracorporeal membrane oxygenation therapy (ECMO) have more intracerebral hemorrhages MESHD ( ICH MESHD) compared to other ARDS MESHD patients.Methods: We conducted a retrospective observational single center study enrolling all patients with ARDS MESHD from 01/2018-05/2020. Patients with ARDS MESHD positive for SARS-CoV2 PCR were allocated to the COVID-19 group. Propensity score matching was performed for age TRANS, ECMO and risk of bleeding MESHD according to HAS-BLED score.Results: A total of 163, mostly severe ARDS MESHD patients were identified, 116 (71.2%) without COVID-19 and 47 (28.8%) positive for SARS-CoV-2. The two groups were comparable concerning the main confounders of ICH MESHD including age TRANS, HAS-BLED score, need for ECMO-therapy as well as anticoagulation levels reported. In 63/163 cases (38.7%), veno-venous ECMO therapy was required and ICU survival was 52.8%. Although HAS-BLED-score on admission was generally low (1.6±1.3), intracerebral hemorrhage MESHD was detected in 22 patients (13.5%) with no statistical difference between the groups (11.2 vs. 19.1% with and without SARS-CoV-2, respectively, p=0.21). Propensity score matching confirmed similar intracerebral bleeding MESHD rates in both groups (12.8 vs. 19.1% with and without SARS-CoV-2, respectively, p=0.57). Conclusions: Intracerebral hemorrhage MESHD was detectable in every tenth patient with ARDS MESHD. We found no statistically significant increased bleeding MESHD rate in patients with ARDS MESHD due to COVID-19 compared to other causes of ARDS MESHD.

    COVID-19 CT Image Synthesis with a Conditional Generative Adversarial Network

    Authors: Yifan Jiang; Han Chen; Murray Loew; Hanseok Ko

    id:2007.14638v1 Date: 2020-07-29 Source: arXiv

    Coronavirus disease MESHD 2019 (COVID-19) is an ongoing global pandemic that has spread rapidly since December 2019. Real-time reverse transcription polymerase chain reaction (rRT-PCR) and chest computed tomography (CT) imaging both play an important role in COVID-19 diagnosis. Chest CT imaging offers the benefits of quick reporting, a low cost, and high sensitivity SERO for the detection of pulmonary infection MESHD. Recently, deep-learning-based computer vision methods have demonstrated great promise for use in medical imaging applications, including X-rays, magnetic resonance imaging, and CT imaging. However, training a deep-learning model requires large volumes of data, and medical staff faces a high risk when collecting COVID-19 CT data due to the high infectivity of the disease. Another issue is the lack of experts available for data labeling. In order to meet the data requirements for COVID-19 CT imaging, we propose a CT image synthesis approach based on a conditional generative adversarial network that can effectively generate high-quality and realistic COVID-19 CT images for use in deep-learning-based medical imaging tasks. Experimental results show that the proposed method outperforms other state-of-the-art image synthesis methods with the generated COVID-19 CT images and indicates promising for various machine learning applications including semantic segmentation and classification.

    Significant increase in the incidence of high-risk pulmonary embolism HP pulmonary embolism MESHD during the COVID-19 shutdown: the pandemic response causes serious collateral consequences

    Authors: Paul Gressenberger; Thomas Gary; Reinhard B. Raggam; Andrea Borenich; Gudrun Pregartner; Katharina Gütl; Viktoria Muster; Philipp Jud; Franz Hafner; Peter Rief; Gerald Seinost; Marianne Brodmann

    doi:10.21203/rs.3.rs-46099/v1 Date: 2020-07-20 Source: ResearchSquare

    Background Strict stay-at-home rules, along with fear of coronavirus infection MESHD, have kept many patients from timely seeking medical attention during the novel coronavirus disease (COVID-19) pandemic. This situation may have led to an increase in the number of patients arriving at hospital in deteriorated clinical condition. In this regard, we aimed to investigate the incidence of pulmonary embolism HP pulmonary embolism MESHD ( PE MESHD) patients defined as high-risk according to the European Society of Cardiology (ESC) presenting at our emergency department during the shutdown.Methods A retrospective data analysis explored the impact of the COVID-19 shutdown on the presentation of acute PE MESHD patients admitted to University Hospital Graz, Austria. We compared percentages of high-risk PE MESHD patients admitted during shutdown and during two control periods: the corresponding period in 2019 and an earlier period in 2020. By including data from the previous year, a general increase of high risk PE MESHD cases in 2020 compared to 2019 was ruled out. Risk assessment was carried out in accordance with current ESC guidelines for the diagnosis and management of acute PE MESHD.Results The percentage of patients with high-risk PE MESHD increased significantly during the COVID-19 shutdown period compared to the two control periods (p = 0.003; p = 0.011). Time from onset of symptoms TRANS to hospital admission was significantly longer in the study period compared to the control periods (p = 0.046 and p = 0.044, respectively).Conclusion The current findings indicate a significant increase in high-risk PE MESHD cases as well as delayed hospital admission of symptomatic PE MESHD patients during the COVID-19 shutdown period.

    Acute Pulmonary Embolism HP Pulmonary Embolism MESHD in Coronavirus Disease 2019

    Authors: Yanan Guo; Wenwu Sun; Yanli Liu; Yanling Lv; Su Zhao; Liangkai Chen; Zhengqing Liu; Li Yu

    doi:10.21203/rs.3.rs-41996/v1 Date: 2020-07-13 Source: ResearchSquare

    Background Pulmonary embolism HP Pulmonary embolism MESHD is a severe condition prone to misdiagnosis given its nonspecific signs and symptoms. Previous studies on the pneumonia HP outbreak caused by coronavirus disease MESHD 2019 (COVID-19) showed a number of patients with elevated d-dimer, whether those patients combined with pulmonary embolism HP pulmonary embolism MESHD got our attention. Methods Data on clinical manifestations, laboratory and radiological findings, treatment, and disease progression of 19 patients with laboratory-confirmed COVID-19 pneumonia HP pneumonia MESHD,who completed computed tomographic pulmonary angiography (CTPA) during hospitalization in the Central Hospital of Wuhan from January 2 to March 26, 2020, were reviewed. Results Of the 19 suspected pulmonary embolism HP pulmonary embolism MESHD and subjected to CTPA patients, six were diagnosed with pulmonary embolism HP pulmonary embolism MESHD. The Wells’ score of the six patients with pulmonary embolism HP pulmonary embolism MESHD was 0–1, which suggested a low risk of pulmonary embolism HP pulmonary embolism MESHD. The median level of d-dimers collected at the day before or on the day of CTPA completion in the patients with pulmonary embolism HP pulmonary embolism MESHD was 18.36 (interquartile range [IQR]: 6.69–61.46) µg/mL, which was much higher than that in the patients without pulmonary embolism HP pulmonary embolism MESHD (median 9.47 [IQR: 4.22–28.02] µg/mL). Of the 6 patients diagnosed with pulmonary embolism HP pulmonary embolism MESHD, all patients received anticoagulant therapy, 5 of which survived and were discharged and 1 died. Conclusion A potential causal relationship exists between COVID-19 infection MESHD and pulmonary embolism HP pulmonary embolism MESHD, but whether this phenomenon is common remains uncertain. The clinical manifestations of COVID-19 patients who developed pulmonary embolism HP pulmonary embolism MESHD are similar to those of patients with increased d-dimer alone, prompting a significant challenge on differential diagnoses.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.